Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | PHASE1 | COMPLETED | 12 | — | — | Apr 2, 2002 | Oct 10, 2003 | Nov 17, 2020 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| Interferon-beta | GENETIC | - |
Inclusion Criteria: 1. Must be greater than or equal to 18 years of age. 2. Subjects must have histologically proven GBM, AA, AMO, malignant astrocytoma NOS or gliosarcoma and recurrent or progressive tumor following prior treatment. 3. Tumor must be amenable to radical resection, and resection mus...